Bromelain For Stomach Pain Clinical Trial 2026

Updated for 2026 | Evidence-Based Review | Reading Time: ~14 minutes

---

Table of Contents

1. What Is Bromelain and Why Are Researchers Studying It for Stomach Pain?
2. The Clinical Trial Landscape: What Studies Actually Exist?
3. 2023 Meta-Analysis: The Most Rigorous Pain Data to Date
4. 2025 Ulcerative Colitis RCT: The Closest We Have to a GI-Specific Trial
5. 2026 Research Updates: What Frontiers in Nutrition and Other Reviews Found
6. Can Bromelain Reduce Gut Inflammation? The Cellular Evidence
7. Bromelain Dosage for Stomach Pain: What Clinical Studies Used
8. Safety Profile: Is Bromelain Safe for Ulcers, Gastritis, or IBS-Like Symptoms?
9. Bromelain Alone vs. Combination Enzyme Formulas: Which Works Better?
10. Bromelain Tea, Extract, and Supplement Forms: Does Delivery Method Matter?
11. Frequently Asked Questions
12. Bottom Line: Should You Use Bromelain for Stomach Pain in 2026?

---

Disclosure: This blog post is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any supplement regimen.

---

What Is Bromelain and Why Are Researchers Studying It for Stomach Pain?

If you've ever eaten fresh pineapple and noticed a slight tingling on your tongue, you've already met bromelain up close. Bromelain is a mixture of proteolytic enzymes — primarily cysteine proteases — extracted from the stem and fruit of Ananas comosus, the pineapple plant. It has been used in traditional medicine across Central and South America for centuries, but it wasn't until the mid-20th century that Western researchers began cataloging its pharmacological properties in any systematic way.

Today, bromelain is one of the most-studied plant-derived enzymes in the world. It appears in the scientific literature in the context of wound healing, post-surgical swelling, sinusitis, arthritis, and increasingly — bromelain stomach pain management and gastrointestinal inflammation.

Why does it attract so much attention for digestive complaints? There are three primary reasons:

1. Proteolytic Activity in the GI Tract Bromelain's enzyme activity isn't fully denatured by stomach acid, especially when taken in enteric-coated or high-concentration formulations. A meaningful fraction survives transit through the upper GI tract, where it may assist in protein digestion and reduce the workload on the pancreas.

2. Anti-Inflammatory Mechanisms Beyond simple digestion, bromelain modulates inflammatory pathways. It has been shown to inhibit pro-inflammatory prostaglandins, reduce NF-κB signaling, and downregulate cytokines including TNF-α, IL-1β, and IL-8 — all of which play roles in gut mucosal inflammation.

3. Growing Clinical Interest Between 2023 and 2026, at least three significant publications have addressed bromelain's relationship with pain and gastrointestinal disease — including a systematic meta-analysis, a randomized controlled trial in ulcerative colitis patients, and a critical review published in Frontiers in Nutrition. This makes 2026 arguably the most data-rich moment in the history of natural bromelain stomach pain research.

Let's go through all of it, piece by piece.

---

---

The Clinical Trial Landscape: What Studies Actually Exist?

One of the most important things to understand before evaluating any supplement is the quality of the evidence base. For bromelain and digestive health specifically, the evidence is real — but it is not uniform, and much of it doesn't perfectly match the clinical scenario most people are asking about: ordinary stomach pain, bloating, or functional digestive discomfort.

Here's an honest breakdown of where the evidence stands as of 2026:

What We Have Good Evidence For:

• Post-surgical pain and swelling — Multiple RCTs and a 2023 meta-analysis
• Inflammatory bowel conditions — A 2025 RCT in ulcerative colitis
• Periodontal and dental pain — A 2023 double-blind crossover trial
• Anti-inflammatory cellular activity in gut epithelial cells — Strong in vitro data

What We Have Limited or No Direct RCT Evidence For:

• Ordinary functional dyspepsia (indigestion without a diagnosable cause)
• Irritable bowel syndrome (IBS)-related stomach cramping
• Gastritis or peptic ulcer-associated stomach pain in humans
• Simple bloating and gas in otherwise healthy adults

This distinction matters. The chamgap.com verdict page, one of the top-ranking sources currently evaluating this topic, explicitly stated in 2026 that no human RCT has been identified proving standalone bromelain improves ordinary digestive discomfort, and that evidence for digestion relief remains limited and conflicting.

That's a fair assessment. But it doesn't mean bromelain is useless for gut-related issues — it means we need to read the available evidence carefully, understand what each study actually measured, and apply that knowledge thoughtfully.

Let's now go through the most clinically meaningful studies in detail.

---

2023 Meta-Analysis: The Most Rigorous Pain Data to Date

The strongest quantitative evidence we currently have for bromelain and stomach pain relief — or more precisely, bromelain and pain relief broadly — comes from a 2023 systematic review and meta-analysis published in the peer-reviewed literature.

Study Overview

The review aggregated data from 9 clinical studies that met inclusion criteria for examining oral bromelain against a control condition in pain-related outcomes. The pooled sample size across these 9 studies was sufficient to run a meta-analysis with meaningful statistical power.

Key Findings

• Pain Reduction: Oral bromelain produced a small but statistically significant reduction in pain scores compared to controls. The mean difference in pain score was −0.27 (95% CI: −0.45 to −0.08).
• Heterogeneity: I² = 29%, which is considered low to moderate heterogeneity — a good sign that results were reasonably consistent across studies.
• Safety: Major health risks were not reported during treatment across included studies.
• Overall Conclusion: The review concluded that moderate-quality studies support the potential use of oral bromelain in pain control.

What Does a Mean Difference of −0.27 Actually Mean?

To put this in plain terms: on a standard 0–10 pain scale, −0.27 means bromelain reduced pain by roughly one-quarter of a point more than placebo. That's statistically meaningful — it's not noise — but it's also modest. This is typical for nutraceutical interventions versus pharmaceutical-grade analgesics.

The clinical significance of this effect size would depend heavily on the individual. For someone with mild to moderate stomach pain or bloating, a 0.27-point reduction on a pain scale might be exactly what they're looking for. For someone with severe, acute abdominal pain, it would be insufficient on its own.

Limitations to Keep in Mind

The 9 studies included in this meta-analysis were not all GI-specific. Several examined musculoskeletal pain, surgical pain, or dental pain. This means we cannot automatically extrapolate a −0.27 mean difference to stomach pain with bromelain specifically. However, given the shared mechanistic pathways (prostaglandin inhibition, cytokine modulation), it's biologically plausible that similar effects operate in gut tissue.

---

2025 Ulcerative Colitis RCT: The Closest We Have to a GI-Specific Trial

If the 2023 meta-analysis is the broadest quantitative evidence, the 2025 ulcerative colitis (UC) trial is the most directly relevant gut-specific clinical trial we currently have.

Study Design

• Design: Randomized, triple-blind, placebo-controlled trial
• Population: 70 patients with mild-to-moderate active ulcerative colitis
• Intervention: 400 mg/day bromelain for 8 weeks
• Control: Matched placebo
• Primary Outcome: Simple Clinical Colitis Activity Index (SCCAI) score
• Secondary Outcome: Quality-of-life (QoL) measures

Results

• Disease Activity (SCCAI): Bromelain significantly improved SCCAI scores compared to placebo. This is clinically meaningful — SCCAI scores reflect the severity of colitis symptoms, including abdominal pain, urgency, bloody stool, and general wellbeing.
• Quality of Life: The change in QoL measures did not reach statistical significance between groups.

What This Tells Us About Bromelain and Stomach Pain

Ulcerative colitis is an inflammatory bowel disease characterized by recurring episodes of gut wall inflammation, which produces real, measurable stomach pain and cramping. When the SCCAI score improves significantly under bromelain treatment, that includes an improvement in the abdominal pain sub-component of that score.

This is, to date, the strongest human clinical trial evidence that bromelain benefits stomach pain in an inflammatory GI context. The fact that QoL didn't change significantly is worth noting — it may reflect that while objective disease markers improved, patients' subjective sense of overall wellbeing lagged behind during the 8-week window, or that QoL is simply a more complex, slower-moving outcome than disease activity scores.

The 400 mg/Day Dose

This is also one of the most specific data points available for anyone asking about bromelain dosage for stomach pain in a clinical context. 400 mg per day, taken over 8 weeks, was the dosing protocol in this placebo-controlled human trial. It produced statistically significant improvement in GI disease activity scores. This is not a theoretical dose — it's one that was tested, monitored, and reported in a peer-reviewed publication.

---

---

2026 Research Updates: What Frontiers in Nutrition and Other Reviews Found

Frontiers in Nutrition Critical Review (2026)

A critical review published in Frontiers in Nutrition in 2026 examined bromelain's broader effects on gastrointestinal health, including ulcer models, gastric acidity, and mucosal protection.

Key findings from animal models included in the review:

• In animal ulcer models, bromelain reduced both free and total gastric acidity and increased gastric pH, suggesting a possible gastroprotective mechanism.
• This is important because elevated gastric acidity is a major driver of stomach pain in conditions like gastritis, peptic ulcers, and GERD.

The critical caveat: These were animal studies, not human clinical trials. The Frontiers in Nutrition review explicitly flagged this limitation. Gastroprotective effects observed in rodent ulcer models cannot be automatically assumed to translate to human bromelain stomach pain management. However, the mechanistic plausibility they establish is genuinely interesting and worth watching in future human trials.

The PMC 2024 Comprehensive Review

A 2024 review published on PubMed Central summarized bromelain's therapeutic potential across multiple organ systems and included specific discussion of its gastrointestinal applications.

GI-specific highlights:

• The review noted that bromelain may mitigate bloating, gas, and abdominal pain through the modulation of inflammatory mediators, including prostaglandins and cytokines.
• Notably, the review also referenced a Phase I/II clinical trial of intratumoral bromelain combined with N-acetylcysteine for recurrent or unresectable pseudomyxoma peritonei — an abdominal cavity tumor. While this is not a stomach pain study in the traditional sense, it underscores that bromelain is considered seriously enough to be enrolled in formal oncological clinical trials targeting abdominal pathology.

The Chamgap Verdict (2026)

The chamgap.com verdict page on bromelain and digestion, currently one of the top-ranking resources for this keyword, issued a sobering but fair assessment in 2026:

No human RCT was identified proving that standalone bromelain improves ordinary digestive discomfort, and evidence for digestion relief remains limited and conflicting.

This is accurate. The 2025 UC trial addresses inflammatory GI disease, not garden-variety indigestion. The meta-analysis addresses pain broadly, not stomach-specific pain. The animal data is mechanistically interesting but not clinically proven in humans.

If someone is asking, "Has a clinical trial proven that bromelain fixes my everyday stomach ache?" — the honest 2026 answer is: not yet, in a direct, dedicated RCT. But the mechanistic evidence, the UC trial data, and the broader pain meta-analysis all point in a direction that makes a future positive RCT plausible.

---

Can Bromelain Reduce Gut Inflammation? The Cellular Evidence

Beyond clinical trials, a critical piece of the bromelain-gut picture comes from cell biology. One particularly compelling study was published in 2021, examining what happens to bromelain's anti-inflammatory activity after it passes through simulated gastrointestinal conditions.

The 2021 Caco-2 Cell Study

• Design: In vitro gastrointestinal digestion simulation followed by testing on Caco-2 cells (human intestinal epithelial cells)
• Key Finding: Bromelain that had been subjected to simulated GI digestion (designed to mimic stomach acid, pancreatic enzymes, and bile) retained strong anti-inflammatory activity in Caco-2 cells, reaching approximately 100% inhibition of IL-8 expression.

Why This Matters

IL-8 is a pro-inflammatory cytokine released by intestinal epithelial cells in response to gut inflammation. Its overproduction is associated with conditions like IBD, gastritis, and intestinal injury. The fact that even partially digested bromelain fragments could suppress IL-8 by up to 100% in gut lining cells is remarkable — and it directly supports the biological plausibility of bromelain extract stomach pain relief working through an anti-inflammatory pathway.

This also partially addresses one of the longstanding criticisms of bromelain stomach pain supplement research: the concern that bromelain is simply denatured by stomach acid before it can do anything useful. The 2021 data suggests that the story is more nuanced — bromelain's degradation products may themselves carry anti-inflammatory activity in the intestinal lining.

---

Bromelain Dosage for Stomach Pain: What Clinical Studies Used

One of the most practical questions readers have is: what dose of bromelain is used in clinical studies? Here's a summary of dosing patterns across the relevant research:

Practical Dosage Guidance Based on Clinical Data

• The best-evidenced dose in a GI-specific human trial is 400 mg/day (the 2025 UC trial).
• Standard supplement doses on the market typically range from 250 mg to 500 mg per serving, often measured in GDU (gelatin digesting units) or MCU (milk clotting units) rather than milligrams of raw extract.
• Enzyme activity matters more than raw weight: a product labeled "500 mg bromelain" with low enzymatic activity may be less effective than a "250 mg" product with high GDU/MCU activity.

When evaluating bromelain dosage for stomach pain in supplements, look for products that list enzyme activity units, not just milligrams. The clinical literature suggests that 400 mg/day of a standardized extract (the UC trial dose) is a reasonable starting reference point for anti-inflammatory GI applications, though individual response will vary.

---

Safety Profile: Is Bromelain Safe for Ulcers, Gastritis, or IBS-Like Symptoms?

General Safety Data

The 2023 meta-analysis explicitly reported that no major health risks were identified during bromelain treatment across the 9 included studies. This is consistent with the broader safety literature for bromelain in oral supplementation contexts.

Specific Concerns and Contraindications

Peptic Ulcers and Gastritis: This is where some nuance is required. Bromelain's proteolytic activity could theoretically irritate already-damaged stomach lining. The 2026 Frontiers in Nutrition review noted that animal studies suggest bromelain may actually be gastroprotective, reducing gastric acidity. However, no human clinical trial has specifically tested bromelain in patients with active peptic ulcers. If you have a diagnosed gastric or duodenal ulcer, you should consult your physician before using bromelain stomach pain supplements.

Allergies: Bromelain is contraindicated in individuals with pineapple allergy. Cross-reactivity may also exist with latex, wheat, celery, papain, and carrot in some individuals.

Blood Thinners: Bromelain has mild anticoagulant properties. It should be used cautiously alongside warfarin, aspirin, or other antiplatelet agents.

Antibiotics: Some research suggests bromelain may enhance the absorption of certain antibiotics, including amoxicillin and tetracycline. This interaction is generally considered potentially beneficial but should be noted by anyone on these medications.

Pregnancy and Breastfeeding: Evidence is insufficient to confirm safety. Avoid unless directed by a healthcare provider.

IBS and Functional Digestive Symptoms

No dedicated clinical trial has enrolled IBS patients specifically for a bromelain intervention. The indirect evidence — anti-inflammatory properties, IL-8 inhibition in gut epithelial cells, improvement in inflammatory GI disease activity — is mechanistically promising for IBS subtypes characterized by low-grade mucosal inflammation, but this is hypothesis-generating, not clinically proven.

---

---

Bromelain Alone vs. Combination Enzyme Formulas: Which Works Better?

Another common question is whether natural bromelain stomach pain relief is better achieved through a standalone product or through a multi-enzyme digestive formula. The evidence has something to say about this.

Standalone Bromelain: What the Evidence Supports

The 2025 UC RCT used standalone bromelain at 400 mg/day and found significant improvement in disease activity. This is meaningful — it demonstrates that bromelain alone, without accessory enzymes, has measurable GI anti-inflammatory effects in humans.

Combination Enzyme Formulas: Theoretical and Practical Arguments

Many commercial bromelain stomach pain supplement products combine bromelain with:

• Papain (another plant protease from papaya)
• Pancreatin or pancreatic enzyme blends (amylase, lipase, protease)
• Pepsin (for upper GI protein digestion)
• Ginger extract or turmeric (complementary anti-inflammatory botanicals)

The argument for combination formulas is intuitive: digestive discomfort often involves inadequate breakdown of multiple macronutrients (proteins, fats, carbohydrates), not just proteins. A formula that includes both proteolytic and lipolytic/amylolytic activity may address bloating and gas more comprehensively than a protease-only supplement.

However, it's important to note: most clinical trial data specifically on bromelain for GI pain used single-ingredient protocols. This means that if a combination formula produces benefit, we can't confidently attribute it to the bromelain component specifically.

Practical Recommendation

If your primary goal is to replicate the protocol used in the 2025 UC trial or the conditions studied in the 2023 meta-analysis, a standardized standalone bromelain extract at 400 mg/day is the most evidence-aligned choice. If your goal is broader digestive support for multiple GI complaints (gas, bloating, fat digestion), a multi-enzyme formula with standardized bromelain may offer complementary benefits.

---

Bromelain Tea, Extract, and Supplement Forms: Does Delivery Method Matter?

People increasingly search for bromelain tea stomach pain remedies as a natural, food-based alternative to capsules. Let's look at what the science says about delivery method.

Fresh Pineapple and Pineapple Juice

Fresh pineapple contains bromelain primarily in the stem (in highest concentrations) and to a lesser extent in the fruit pulp. Commercially available pineapple juice is typically heat-processed, which largely denatures the enzymes.

Bottom line: Eating fresh pineapple provides some bromelain activity, but the dose is not standardized and is generally far below the 400 mg/day used in the UC trial.

Bromelain Tea

Bromelain tea stomach pain remedies typically involve steeping dried pineapple or pineapple core pieces in hot water. There is a significant problem with this approach: bromelain is heat-sensitive. Exposure to temperatures above approximately 60–65°C begins to denature the enzyme structure. Boiling water (100°C) will destroy most bromelain activity.

Bottom line: Bromelain tea may offer some comfort as a warm beverage, and if it contains other anti-inflammatory ingredients (ginger, turmeric), those may contribute benefit. But it is unlikely to deliver meaningful active bromelain enzyme activity. The clinical trial data on bromelain and stomach pain relief used oral capsules, not tea.

Bromelain Extract Capsules (Enteric-Coated vs. Standard)

Bromelain extract stomach pain products come in two primary forms:

1. Standard capsules: Release bromelain in the stomach. Some activity survives gastric conditions, particularly the 2021 Caco-2 research supports that partial digestion products retain anti-inflammatory activity.
2. Enteric-coated capsules: Bypass stomach acid and release bromelain in the small intestine, potentially preserving more intact enzyme for systemic absorption.

For pain modulation and anti-inflammatory effects (the UC trial mechanism), enteric coating may not be strictly necessary, as systemic absorption of bioactive peptides through the GI wall appears to occur even with standard capsules. For protein digestion assistance in the stomach itself, a standard (non-enteric) capsule taken with meals would be more appropriate.

Chewable Tablets and Gummies

These are increasingly popular but enzyme stability in these delivery formats can be variable. Heat and moisture during manufacturing may reduce enzymatic activity. Look for products with guaranteed GDU/MCU activity on the label.

The Best Bromelain for Stomach Pain: Key Label Criteria

When searching for the best bromelain for stomach pain, look for:

• ✅ Standardized enzyme activity listed in GDU (Gelatin Digesting Units) — a minimum of 1,800–2,400 GDU/gram is a reasonable quality indicator
• ✅ Third-party testing certificate (USP, NSF, or Informed Sport)
• ✅ Dosage aligning with clinical evidence (≥400 mg/day for anti-inflammatory GI use)
• ✅ No unnecessary fillers, binders, or allergens
• ✅ Transparent labeling of both mg weight AND enzyme activity units

---

---

Frequently Asked Questions

Does bromelain help stomach pain or bloating?

Based on the available 2026 evidence, bromelain shows the most promise for stomach pain related to gut inflammation (as demonstrated in the 2025 UC trial). For general bloating or functional gas, the evidence is more limited — no standalone human RCT has confirmed bromelain's effectiveness for ordinary digestive discomfort specifically. However, its anti-inflammatory and proteolytic properties provide a plausible biological rationale for benefit, and the 2024 PMC review noted its potential for mitigating bloating and abdominal pain through inflammatory mediator modulation.

Is there a human clinical trial for bromelain and digestive discomfort?

Yes — the most relevant human clinical trial is the 2025 randomized, triple-blind, placebo-controlled trial in 70 ulcerative colitis patients. It used 400 mg/day of bromelain for 8 weeks and found significantly improved disease activity scores (including abdominal pain components) compared to placebo. This is not a trial in healthy adults with casual indigestion, but it is direct evidence of bromelain's efficacy against GI pain and inflammation in a human RCT context.

What dose of bromelain is used in clinical studies?

The best-evidenced human GI dose is 400 mg/day (2025 UC RCT). The broader pain meta-analysis pooled studies using various doses, typically in the 100–500 mg range. For enzyme activity, standardized extracts of at least 1,800 GDU/gram are generally considered therapeutically relevant.

Is bromelain safe for people with ulcers, gastritis, or IBS-like symptoms?

The 2023 meta-analysis found no major health risks during treatment. Animal studies suggest possible gastroprotective effects (reduced acidity, higher gastric pH). However, no human trials have enrolled patients with active peptic ulcers, so caution is warranted. Individuals with these conditions should consult a physician before using bromelain stomach pain supplements. For IBS, evidence is indirect but mechanistically suggestive.

Does bromelain work better alone or in combination with other enzymes?

The 2025 UC clinical trial used standalone bromelain and produced significant results. Combination enzyme formulas may offer broader digestive support but lack the same level of direct clinical evidence attributable to bromelain specifically.

Can bromelain reduce inflammation in the gut?

Yes — the 2021 in vitro study found that GI-digested bromelain fragments produced approximately 100% inhibition of IL-8 expression in Caco-2 intestinal epithelial cells. IL-8 is a key inflammatory cytokine in gut mucosal disease. The 2025 UC trial also demonstrated a significant reduction in disease activity (an inflammation-driven score) in human patients.

How fast does bromelain start working?

Clinical trial data doesn't always specify the exact time-to-onset for GI effects. The 2023 dental surgery trial found pain differences compared to ibuprofen at specific time points (ibuprofen was lower only at 4 hours post-op, after which bromelain was comparable), suggesting bromelain's anti-inflammatory effect may take slightly longer to peak than fast-acting NSAIDs. For chronic GI conditions, the UC trial used an 8-week protocol, suggesting that anti-inflammatory benefits in gut tissue accumulate over weeks rather than hours.

Are there any recent 2024–2026 studies on bromelain and gastrointestinal symptoms?

Yes — three significant publications emerged:

• 2024 PMC review: Bromelain's potential for bloating, gas, and abdominal pain through inflammatory mediator modulation; Phase I/II trial for intraabdominal pseudomyxoma peritonei noted.
• 2025 RCT: 400 mg/day bromelain in ulcerative colitis — significant improvement in disease activity score.
• 2026 Frontiers in Nutrition review: Animal data showing gastroprotective effects (reduced acidity, higher gastric pH); not a human trial.

---

Bottom Line: Should You Use Bromelain for Stomach Pain in 2026?

Here is the most honest, evidence-based summary of where bromelain for stomach pain stands in 2026:

What the Evidence Clearly Supports:

• Oral bromelain produces a small but statistically significant reduction in pain versus placebo (meta-analysis, mean difference −0.27, moderate-quality evidence)
• 400 mg/day bromelain for 8 weeks significantly improved disease activity in a placebo-controlled human trial of GI inflammation (UC)
• Bromelain's digestion products retain potent anti-inflammatory activity in gut epithelial cells (up to 100% IL-8 inhibition in Caco-2 cells)
• Major health risks were not reported in clinical studies reviewed

What Remains Unproven:

• Standalone bromelain improving ordinary functional digestive discomfort in healthy adults (no dedicated human RCT)
• Efficacy for IBS, gastritis, or peptic ulcer pain in humans (mechanistically plausible, not clinically proven)
• Bromelain tea as a meaningful delivery method for active enzyme therapy

The 2026 Verdict in Plain Language

Bromelain is not a miracle cure for stomach pain, but it is not a placebo either. The clinical evidence, particularly the 2025 RCT and 2023 meta-analysis, shows real, measurable anti-inflammatory and analgesic effects in human subjects. The 2021 cellular data confirms that these effects extend into the gut lining specifically.

If your stomach pain has an inflammatory component — IBD, colitis, or post-meal inflammation — the case for trying a standardized bromelain stomach pain supplement at approximately 400 mg/day is supported by human clinical trial data. If your stomach pain is more functional or stress-related, bromelain may still offer modest benefit through its enzyme and anti-inflammatory activity, but don't expect dramatic results and don't skip a proper medical evaluation.

The most important next step in this field is a well-designed RCT targeting functional dyspepsia or IBS specifically with a standardized oral bromelain extract. Until that trial exists, what we have is compelling circumstantial and disease-model evidence — enough to take seriously, not enough to treat as definitive proof for all forms of stomach pain.

As always, use this information to have a better-informed conversation with your gastroenterologist or primary care provider — not to replace one.

---

References available on request. This article synthesizes publicly available research including the 2023 systematic meta-analysis, the 2025 UC randomized controlled trial, the 2026 Frontiers in Nutrition critical review, the 2024 PMC therapeutic review, and the 2021 in vitro Caco-2 digestion study. All statistical data is cited as published in the respective studies.

---